Quick Answer
ZyVersa Therapeutics, Inc. reported Total Assets of $347.9 thousand for fiscal year 2025.
ZyVersa Therapeutics, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $347.9K | -98.3% |
| 2024 | $20.60M | -6.9% |
| 2023 | $22.11M | -81.3% |
| 2022 | $118.51M | +53.6% |
| 2021 | $77.14M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.04M | -94.6% | -94.7% |
| June 30, 2025 | $19.64M | +0.9% | -6.4% |
| March 31, 2025 | $20.99M | -3.1% | +1.9% |
| December 31, 2024 | $20.60M | -6.9% | +6.1% |
| September 30, 2024 | $19.42M | -40.9% | -0.2% |
| June 30, 2024 | $19.47M | -39.1% | -10.1% |
| March 31, 2024 | $21.65M | -81.2% | -2.1% |
| December 31, 2023 | $22.11M | -81.3% | -32.7% |
- ZyVersa Therapeutics, Inc. showed a decrease of -98.3% in Total Assets compared to the prior fiscal year.
- Over the 2021–2025 period, ZyVersa Therapeutics, Inc.’s total assets has declined by 99.5% (from $77.14 million to $347.9 thousand).
- The most recent figure is from ZyVersa Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: